Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis.
Loibl S, Skacel T, Nekljudova V, Lück HJ, Schwenkglenks M, Brodowicz T, Zielinski C, von Minckwitz G. Loibl S, et al. Among authors: von minckwitz g. BMC Cancer. 2011 Apr 12;11:131. doi: 10.1186/1471-2407-11-131. BMC Cancer. 2011. PMID: 21486442 Free PMC article. Clinical Trial.
Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
Loibl S, Murmann C, Schwedler K, Warm M, Müller L, Heinrich G, Nekljudova V, von Minckwitz G. Loibl S, et al. Among authors: von minckwitz g. Cancer Chemother Pharmacol. 2009 Apr;63(5):953-8. doi: 10.1007/s00280-008-0821-8. Epub 2008 Aug 21. Cancer Chemother Pharmacol. 2009. PMID: 18716777 Clinical Trial.
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.
Loibl S, von Minckwitz G, Harbeck N, Janni W, Elling D, Kaufmann M, Eggemann H, Nekljudova V, Sommer H, Kiechle M, Kümmel S. Loibl S, et al. Among authors: von minckwitz g. Breast Cancer Res. 2008;10(5):R77. doi: 10.1186/bcr2144. Epub 2008 Sep 16. Breast Cancer Res. 2008. PMID: 18796139 Free PMC article.
Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33).
Loibl S, Mueller V, von Minckwitz G, Conrad B, Koehne CH, Kremers S, Forstbauer H, Linder M, Nekljudova V, Moebus V; GBG/AGO/NOGGO study groups. Loibl S, et al. Among authors: von minckwitz g. Support Care Cancer. 2011 Nov;19(11):1789-95. doi: 10.1007/s00520-010-1020-9. Epub 2010 Oct 16. Support Care Cancer. 2011. PMID: 20953803 Clinical Trial.
Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.
von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Lück HJ, Maass N, Zielinski C, Andersson M, Stein RC, Nekljudova V, Loibl S; GBG 26/BIG 03-05 study group and participating investigators. von Minckwitz G, et al. Eur J Cancer. 2011 Oct;47(15):2273-81. doi: 10.1016/j.ejca.2011.06.021. Epub 2011 Jul 7. Eur J Cancer. 2011. PMID: 21741829 Clinical Trial.
Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials.
Fontanella C, Lederer B, Gade S, Vanoppen M, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Schneeweiss A, Paepke S, Jackisch C, Mehta K, Nekljudova V, Untch M, Neven P, von Minckwitz G, Loibl S. Fontanella C, et al. Among authors: von minckwitz g. Breast Cancer Res Treat. 2015 Feb;150(1):127-39. doi: 10.1007/s10549-015-3287-5. Epub 2015 Feb 13. Breast Cancer Res Treat. 2015. PMID: 25677740
Evolution of adjuvant chemotherapy for breast cancer.
von Minckwitz G, Loibl S. von Minckwitz G, et al. Lancet. 2015 May 9;385(9980):1812-4. doi: 10.1016/S0140-6736(14)62348-5. Epub 2015 Mar 2. Lancet. 2015. PMID: 25740287 No abstract available.
Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials.
Loibl S, Jackisch C, Lederer B, Untch M, Paepke S, Kümmel S, Schneeweiss A, Huober J, Hilfrich J, Hanusch C, Gerber B, Eidtmann H, Denkert C, Costa SD, Blohmer JU, Nekljudova V, Mehta K, von Minckwitz G. Loibl S, et al. Among authors: von minckwitz g. Breast Cancer Res Treat. 2015 Jul;152(2):377-87. doi: 10.1007/s10549-015-3479-z. Epub 2015 Jun 25. Breast Cancer Res Treat. 2015. PMID: 26109347
A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
von Minckwitz G, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, Hackmann J, Möbus V, Marmé F, Potenberg J, Stickeler E, Simon E, Thomssen C, Huober J, Denkert C, Alfer J, Jackisch C, Nekljudova V, Burchardi N, Loibl S; German Breast Group Investigators. von Minckwitz G, et al. Cancer. 2015 Oct 15;121(20):3639-48. doi: 10.1002/cncr.29506. Epub 2015 Jun 25. Cancer. 2015. PMID: 26111104 Free article. Clinical Trial.
368 results